These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 2496877

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Methylprednisolone in the treatment of exophthalmos.
    Garber MI.
    Lancet; 1966 Apr 30; 1(7444):958-60. PubMed ID: 4160651
    [No Abstract] [Full Text] [Related]

  • 3. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy.
    Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G, Fenzi G.
    J Endocrinol Invest; 2001 Mar 30; 24(3):152-8. PubMed ID: 11314743
    [Abstract] [Full Text] [Related]

  • 4. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
    Colao A, Lastoria S, Ferone D, Pivonello R, Macchia PE, Vassallo P, Bonavolonta G, Muto P, Lombardi G, Fenzi G.
    J Clin Endocrinol Metab; 1998 Nov 30; 83(11):3790-4. PubMed ID: 9814448
    [Abstract] [Full Text] [Related]

  • 5. Early effects of methylprednisolone infusion on serum cystatin C in patients with severe Graves' ophthalmopathy.
    Manetti L, Genovesi M, Pardini E, Grasso L, Lupi I, Linda Morselli L, Pellegrini G, Martino E.
    Clin Chim Acta; 2005 Jun 30; 356(1-2):227-8. PubMed ID: 15936323
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M, Pinchera A.
    J Clin Endocrinol Metab; 2001 Aug 30; 86(8):3562-7. PubMed ID: 11502779
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M, Siemińska L, Karpe J, Marek B, Kos-Kudła B, Kajdaniuk D.
    J Endocrinol Invest; 2016 Jan 30; 39(1):63-72. PubMed ID: 26062519
    [Abstract] [Full Text] [Related]

  • 10. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM.
    Lancet Diabetes Endocrinol; 2017 Feb 30; 5(2):134-142. PubMed ID: 27346786
    [Abstract] [Full Text] [Related]

  • 11. Utility of rituximab treatment for exophthalmos, myxedema, and osteoarthropathy syndrome resistant to corticosteroids due to Graves' disease: a case report.
    Ferreira-Hermosillo A, Casados-V R, Paúl-Gaytán P, Mendoza-Zubieta V.
    J Med Case Rep; 2018 Feb 16; 12(1):38. PubMed ID: 29448964
    [Abstract] [Full Text] [Related]

  • 12. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids.
    Myśliwiec J, Kretowski A, Topolska J, Siewko K, Jakubczyk D, Szelachowska M, Mikita A, Kinalska I.
    Horm Metab Res; 2001 Dec 16; 33(12):739-43. PubMed ID: 11753760
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Malignant exophthalmos treated with methylprednisolone acetate].
    Roelsen E, Skjoerboek-Olesen O.
    Ugeskr Laeger; 1968 Jan 04; 130(1):13-5. PubMed ID: 5694738
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Serum Fas in patients with Graves' ophthalmopathy as a marker of activity of the ocular inflammatory infiltration].
    Myśliwiec J, Kretowski A, Stepień A, Okłota M, Kinalska I.
    Pol Merkur Lekarski; 2004 Oct 04; 17(100):368-70. PubMed ID: 15690704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.